Literature DB >> 14599087

Update on the treatment of neuroendocrine tumors.

Emilio Bajetta1, Giuseppe Procopio, Leonardo Ferrari, Laura Catena, Michele Del Vecchio, Emilio Bombardieri.   

Abstract

Neuroendocrine tumors represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. The basic study of the biological features of neuroendocrine tumors should allow the oncologist to identify those tumor subsets more sensitive to a particular medical treatment. For example, in metastatic or advanced disease, locoregional treatments, as well as radionuclide therapies, should be suggested only in selected cases. Although it has no significant effect on tumor growth, biotherapy with somatostatin analogs and/or interferon-alpha is recommended for either well-differentiated or functioning tumors. On the other hand, chemotherapy is effective in the treatment of those tumors characterized by a poor differentiation grade and a high proliferation rate. Novel therapies, new pharmacological formulations and more selective somatostatin analogs are now under clinical investigation for the treatment of neuroendocrine tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14599087     DOI: 10.1586/14737140.3.5.631

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  9 in total

1.  Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine.

Authors:  Gianluca Masi; Lorenzo Fornaro; Samanta Cupini; Fotios Loupakis; Enrico Vasile; Giacomo G Baldi; Irene Stasi; Lisa Salvatore; Alfredo Falcone
Journal:  Nat Rev Clin Oncol       Date:  2009-11       Impact factor: 66.675

2.  Patient with synchronous low grade leiomyosarcoma of the thigh, primary pancreatic neuroendocrine tumor, and lung metastases: Why biopsy of metastases should be the standard.

Authors:  Jesus Fabregas; Tony N Talebi; Caio Rocha Lima; George N Sfakianakis; Philip Robinson; Alberto J Montero
Journal:  J Gastrointest Oncol       Date:  2011-06

3.  Prognosis and risk factors of metastasis in colorectal carcinoids: results of a nationwide registry over 15 years.

Authors:  Tsuyoshi Konishi; Toshiaki Watanabe; Junji Kishimoto; Kenjiro Kotake; Tetsuichiro Muto; Hirokazu Nagawa
Journal:  Gut       Date:  2007-01-09       Impact factor: 23.059

4.  X-linked hyper-IgM syndrome associated with poorly differentiated neuroendocrine tumor presenting as obstructive jaundice secondary to extensive adenopathy.

Authors:  Nandini Nagaraj; Chukwuma Egwim; Douglas G Adler
Journal:  Dig Dis Sci       Date:  2007-04-12       Impact factor: 3.199

5.  Everolimus for advanced pancreatic neuroendocrine tumors.

Authors:  James C Yao; Manisha H Shah; Tetsuhide Ito; Catherine Lombard Bohas; Edward M Wolin; Eric Van Cutsem; Timothy J Hobday; Takuji Okusaka; Jaume Capdevila; Elisabeth G E de Vries; Paola Tomassetti; Marianne E Pavel; Sakina Hoosen; Tomas Haas; Jeremie Lincy; David Lebwohl; Kjell Öberg
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

6.  Elevated Serum Amino Acids Induce a Subpopulation of Alpha Cells to Initiate Pancreatic Neuroendocrine Tumor Formation.

Authors:  Derek K Smith; Lance Kates; Steffen Durinck; Nisha Patel; Eric W Stawiski; Noelyn Kljavin; Oded Foreman; Bence Sipos; Mark J Solloway; Bernard B Allan; Andrew S Peterson
Journal:  Cell Rep Med       Date:  2020-08-25

7.  Neuroendocrine carcinoma arising from the septum. A very rare nasal tumour.

Authors:  E Iacovou; A Chrysovergis; A Eleftheriadou; I Yiotakis; D Kandiloros
Journal:  Acta Otorhinolaryngol Ital       Date:  2010-12-29       Impact factor: 2.124

8.  Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation.

Authors:  P Correale; A Sciandivasci; C Intrivici; A Pascucci; M T Del Vecchio; S Marsili; V Savelli; L Voltolini; M Di Bisceglie; A Guarnieri; G Gotti; G Francini
Journal:  Br J Cancer       Date:  2007-04-17       Impact factor: 7.640

9.  Difficulty of predicting lymph node metastasis on CT in patients with rectal neuroendocrine tumors.

Authors:  Hajime Ushigome; Yosuke Fukunaga; Toshiya Nagasaki; Takashi Akiyoshi; Tsuyoshi Konishi; Yoshiya Fujimoto; Satoshi Nagayama; Masashi Ueno
Journal:  PLoS One       Date:  2019-02-11       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.